FDA Panel Cancels HIV Drug Meeting

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

ROCKVILLE, Md-The FDA has postponed a meeting of its Antiviral Drugs Advisory Committee that was to consider Rescriptor (delavirdine), a Pharmacia and Upjohn Co. drug for use in treating HIV infection. The agency said the postponement will allow time to incorporate results of additional study information that recently became available. The FDA said it will reschedule the meeting, but announced no date.

ROCKVILLE, Md—The FDA has postponed a meeting of its Antiviral Drugs Advisory Committee that was to consider Rescriptor (delavirdine), a Pharmacia and Upjohn Co. drug for use in treating HIV infection. The agency said the postponement will allow time to incorporate results of additional study information that recently became available. The FDA said it will reschedule the meeting, but announced no date.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content